{"filing":{"accession_number":"0001439222-26-000115","cik":"0001439222","ticker":"AGIO","company_name":"AGIOS PHARMACEUTICALS, INC.","form":"8-K","filing_date":"2026-07-30","report_date":"2026-07-30","primary_document":"agio-20260730.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000115/agio-20260730.htm"},"events":[{"id":21953,"run_id":19822,"accession_number":"0001439222-26-000115","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"This is a clear earnings release disclosing Agios Pharmaceuticals' second quarter 2026 financial results. The filing explicitly states \"On July 30, 2026, Agios Pharmaceuticals, Inc. issued a press release announcing its results for the quarter ended June 30, 2026\" and includes consolidated balance sheet and statements of operations data showing net product revenue of $44.7 million and net loss of $100.7 million for Q2 2026. The press release is furnished as Exhibit 99.1 and contains detailed financial results and business highlights typical of a quarterly earnings announcement.","company_name":"AGIOS PHARMACEUTICALS, INC.","ticker":"AGIO","filing_date":"2026-07-30","form":"8-K","submitted_at":null,"items":[{"id":21740,"accession_number":"0001439222-26-000115","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Agios Pharmaceuticals' second quarter 2026 financial results. The filing explicitly states \"On July 30, 2026, Agios Pharmaceuticals, Inc. issued a press release announcing its results for the quarter ended June 30, 2026\" and includes consolidated balance sheet and statements of operations data showing net product revenue of $44.7 million and net loss of $100.7 million for Q2 2026. The press release is furnished as Exhibit 99.1 and contains detailed financial results and business highlights typical of a quarterly earnings announcement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-30T10:34:00.134001+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":21740,"accession_number":"0001439222-26-000115","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Agios Pharmaceuticals' second quarter 2026 financial results. The filing explicitly states \"On July 30, 2026, Agios Pharmaceuticals, Inc. issued a press release announcing its results for the quarter ended June 30, 2026\" and includes consolidated balance sheet and statements of operations data showing net product revenue of $44.7 million and net loss of $100.7 million for Q2 2026. The press release is furnished as Exhibit 99.1 and contains detailed financial results and business highlights typical of a quarterly earnings announcement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-30T10:34:00.134001+00:00","company_name":"AGIOS PHARMACEUTICALS, INC.","ticker":"AGIO","filing_date":"2026-07-30"}]}